Press Release

CluePoints Supports Launch of RBQM Live 2023 as Premier Event Sponsor

Registration for must-attend Risk-Based Quality Management event is now open.

King of Prussia, PA  – May 3, 2023: CluePoints, the premier provider of Risk-Based Study Execution (RBx) and Risk-Based Quality Management (RBQM) Software for clinical trials, has launched registration for RBQM Live 2023, the foremost virtual event known for shaping the future of RBQM.

This year, the free-to-attend event, which takes place from September 6-7 including a workshop on Risk-Based Data Management on September 8, is a must-attend for anyone working with, or planning to adopt, Risk-Based Quality Management (RBQM) and risk-based approaches in general within clinical trials. Sponsored by CluePoints, all sessions are free, but registration is essential as places are limited.

RBQM Live provides a unique opportunity to discuss the current RBQM landscape, look ahead to the future, and share practical experiences. There is something for everyone, no matter the size or type of organization or the delegate’s experience.

Day 1 on September 6, 2023, will focus on how RBQM has recently transformed. The keynote address, The Global Transformation of RBQM – Research Study Findings from a 2023 Survey and Executive Roundtable Discussions, will be given by Ken Getz, Executive Director and Professor, Tufts Center for the Study of Drug Development.

Other highlights include technology showcases, a briefing on ICH E6 (R3) & E8 guidance updates, and a masterclass on understanding RBQM during the design and planning process.

Day 2, on September 7, 2023, focuses on technology with a keynote panel discussion titled ‘The RBQM Journey: Understanding RBQM Technology Evolution and How to Navigate the Future.’

Other highlights include a panel discussion on the evolution of adaptive QTLs and a masterclass on understanding the RBQM process and documentation phase.

On September 8, 2023, the event will also offer a ‘Risk-Based Data Management Revolution’ workshop.

Patrick Hughes, Co-Founder and Chief Commercial Officer of CluePoints, commented, “Risk-Based Quality Management is continuing to grow and transform the clinical trials space. We are delighted to be once again bringing together industry leaders to share their expertise and experience at RBQM Live. These sessions are designed to help you and your team succeed with RBQM – whether you are considering adopting it for the first time or looking to build on your existing approaches. There is something in it for everyone as we all contribute to this paradigm shift in adopting RBQM.”

RBQM Live 2023 takes place from September 6 to September 7, including the workshop on the 8th. For more information and to register for your free spot, visit The full speaker line-up will be announced in early June.

About CluePoints

CluePoints is the premier Risk-Based Quality Management (RBQM) and Data Quality Oversight Software provider. Our products utilize comprehensive statistical algorithms to determine the quality, accuracy, and integrity of clinical trial data both during and after study conduct. Aligned with guidance from the FDA, EMA, and ICH E6 (R2), CluePoints® is deployed to support central and on-site monitoring, medical review, quality risk management and to drive a holistic Risk-Based strategy in all trials. Coupled with thought leadership and consulting expertise to aid pre-study risk assessment, identification of risk controls and solution implementation you now have everything you need to adhere with global regulatory guidance. The result is increased operational efficiency, lower costs and reduced regulatory submission risk as part of the industry paradigm shift to RBQM.

Press Release
CluePoints, a Leading Provider of AI-Driven Software Solutions for Clinical Data Review, Receives Significant Investment for Continued Growth from EQT
Press Release
CluePoints Brand Evolution Confirms Commitment to ‘Turning Artificial Intelligence into Human Intelligence’
Press Release
FDA And CluePoints Sign New 3 Year Cooperative Research And Development Agreement To Assess Data Quality Using Statistical Modelling And Machine Learning